Small-molecule inhibitors of the Serum Response Factor in combination with enzalutamide: New strategy to treat castrate-resistant prostate cancer

Serum Response Factor ◽

Response Factor ◽

New Strategy ◽

Castrate Resistant ◽

Abstract 4599: Negative feedback loop between serum response factor and androgen receptor in castrate-resistant prostate cancer

10.1158/1538-7445.am2014-4599 ◽

2014 ◽

Author(s):

Maria Prencipe ◽

Gillian O'Hurley ◽

Amanda O'Neill ◽

Dara Lundon ◽

Lan K. Nguyen ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Receptor ◽

Negative Feedback ◽

Feedback Loop ◽

Serum Response Factor ◽

Negative Feedback Loop ◽

Response Factor ◽

Castrate Resistant ◽

545 DHT Regulates Serum Response Factor Transcription Activity in Castrate-resistant Prostate Cancer Cell Lines

European Journal of Cancer ◽

10.1016/s0959-8049(12)72342-0 ◽

2012 ◽

Vol 48 ◽

pp. 167-168 ◽

Cited By ~ 1

Author(s):

M. Prencipe ◽

A. O'Neill ◽

G. O'Hurley ◽

H. Klocker ◽

E.W. Kay ◽

...

Keyword(s):

Prostate Cancer ◽

Cell Lines ◽

Serum Response Factor ◽

Prostate Cancer Cell ◽

Response Factor ◽

Prostate Cancer Cell Lines ◽

Transcription Activity ◽

Castrate Resistant ◽

Abstract 1575: Novel small molecule inhibitors of p300/CBP down-regulate AR and c-Myc for the treatment of castrate resistant prostate cancer

10.1158/1538-7445.am2017-1575 ◽

2017 ◽

Cited By ~ 1

Author(s):

Nigel Brooks ◽

Neil Pegg ◽

Jenny Worthington ◽

Barbara Young ◽

Amy Prosser ◽

...

Keyword(s):

Prostate Cancer ◽

Small Molecule ◽

Abstract B091: Small-molecule inhibitors targeting a specific metabolic pathway for precision therapy of advanced castrate-resistant prostate cancer

10.1158/1538-7445.prca2017-b091 ◽

2018 ◽

Author(s):

Hirak Basu ◽

Nathaniel Wilganowski ◽

Jessica Lieblich ◽

Grace Wu ◽

Izabela Fokt ◽

...

Keyword(s):

Prostate Cancer ◽

Small Molecule ◽

Metabolic Pathway ◽

Precision Therapy ◽

Emerging Non-Canonical Small-Molecule Inhibitors of Androgen Receptor (AR) and AR Interactome Partners for the Treatment of Castrate-Resistant Prostate Cancer

2018 Medicinal Chemistry Reviews - Medicinal Chemistry Reviews ◽

10.29200/acsmedchemrev-v53.ch14 ◽

2018 ◽

pp. 267-288

Author(s):

David B. Freeman ◽

André Ri ◽

Marius S. Pop ◽

Nicholas B. Struntz ◽

Angela N. Ko

Keyword(s):

Prostate Cancer ◽

Androgen Receptor ◽

Small Molecule ◽

Inhibition of serum response factor as a new strategy to overcome resistance to enzalutamide in prostate cancer

European Journal of Cancer ◽

10.1016/s0959-8049(20)31207-7 ◽

2020 ◽

Vol 138 ◽

pp. S49

Author(s):

W. Watson ◽

C. Gonzalez ◽

N. Russell ◽

H. Azam ◽

E. Corey ◽

...

Keyword(s):

Prostate Cancer ◽

Serum Response Factor ◽

Response Factor ◽

New Strategy ◽

Inhibition of the Androgen Receptor Amino-Terminal Domain by a Small Molecule as Treatment for Castrate-Resistant Prostate Cancer

10.21236/ada590496 ◽

2013 ◽

Author(s):

Stephen R. Plymate

Keyword(s):

Prostate Cancer ◽

Androgen Receptor ◽

Small Molecule ◽

Amino Terminal ◽

Terminal Domain ◽

Castrate Resistant ◽

Amino Terminal Domain

FGFR-4 Arg388 Enhances Prostate Cancer Progression via Extracellular Signal–Related Kinase and Serum Response Factor Signaling

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-10-2858 ◽

2011 ◽

Vol 17 (13) ◽

pp. 4355-4366 ◽

Cited By ~ 34

Author(s):

Wendong Yu ◽

Shu Feng ◽

Olga Dakhova ◽

Chad J. Creighton ◽

Yi Cai ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Progression ◽

Serum Response Factor ◽

Response Factor ◽

Prostate Cancer Progression ◽

Extracellular Signal ◽

Protein Kinase N1 control of androgen-responsive serum response factor action provides rationale for novel prostate cancer treatment strategy

Oncogene ◽

10.1038/s41388-019-0732-7 ◽

2019 ◽

Vol 38 (23) ◽

pp. 4496-4511

Author(s):

Varadha Balaji Venkadakrishnan ◽

Adam D. DePriest ◽

Sangeeta Kumari ◽

Dhirodatta Senapati ◽

Salma Ben-Salem ◽

...

Keyword(s):

Prostate Cancer ◽

Protein Kinase ◽

Cancer Treatment ◽

Treatment Strategy ◽

Serum Response Factor ◽

Response Factor ◽

Prostate Cancer Treatment ◽

Phase 1 study of the PSMA-targeted tubulysin small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.2586 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 2586-2586

Author(s):

Michael J. Morris ◽

Daniel Peter Petrylak ◽

A. Oliver Sartor ◽

Nicholas J. Vogelzang ◽

Michael Groaning ◽

...

Keyword(s):

Prostate Cancer ◽

Small Molecule ◽

Phase 1 ◽

Phase 1 Study ◽

Drug Conjugate ◽

Small Molecule Drug ◽